Search

Your search keyword '"Trachana, Maria"' showing total 7 results
Start Over Author "Trachana, Maria" Database Supplemental Index
7 results on '"Trachana, Maria"'

1. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results

Author

Brunner, Hermine I., Nanda, Kabita, Toth, Mary, Foeldvari, Ivan, Bohnsack, John, Milojevic, Diana, Rabinovich, C. Egla, Kingsbury, Daniel J., Marzan, Katherine, Chalom, Elizabeth, Horneff, Gerd, Kuester, Rolf‐Michael, Dare, Jason A., Trachana, Maria, Jung, Lawrence K., Olson, Judyann, Minden, Kirsten, Quartier, Pierre, Bereswill, Mareike, Kalabic, Jasmina, Kupper, Hartmut, Lovell, Daniel J., Martini, Alberto, and Ruperto, Nicolino

Abstract

To evaluate safety and effectiveness of adalimumab (ADA) in polyarticular‐course juvenile idiopathic arthritis (JIA) in the STRIVE registry. STRIVE enrolled patients with polyarticular‐course JIA into 2 arms based on treatment with methotrexate (MTX) alone or ADA with/without MTX (ADA ± MTX). Adverse events (AEs) per 100 patient‐years of observation time were analyzed by registry arm. Patients who entered the registry within 4 weeks of starting MTX or ADA ± MTX, defined as new users, were evaluated for change in disease activity assessed by the 27‐joint Juvenile Arthritis Disease Activity Score with the C‐reactive protein level (JADAS‐27CRP). At the 7‐year cutoff date (June 1, 2016), data from 838 patients were available (MTX arm n = 301, ADA ± MTX arm n = 537). The most common AEs were nausea (10.3%), sinusitis (4.7%), and vomiting (4.3%) in the MTX arm and arthritis (3.9%), upper respiratory tract infection (3.5%), sinusitis, tonsillitis, and injection site pain (3.0% each) in the ADA ± MTX arm. Rates of serious infection were 1.5 events/100 patient‐years in the MTX arm and 2.0 events/100 patient‐years in the ADA ± MTX arm. AE and serious AE rates were similar in patients receiving ADA with versus without MTX. No deaths or malignancies were reported. New users in the ADA ± MTX arm showed a trend toward lower mean JADAS‐27CRPcompared with new users in the MTX arm in the first year of STRIVE. The STRIVE registry 7‐year interim results support the idea that ADA ± MTX is well tolerated by most children. Registry median ADA exposure was 2.47 (interquartile range 1.0–3.6) years, with 42% of patients continuing ADA at the 7‐year cutoff date.

Published
2020
Full Text
View/download PDF

2. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood‐Onset Systemic Lupus Erythematosus

Author

Brunner, Hermine I., Holland, Michael J., Beresford, Michael W., Ardoin, Stacy P., Appenzeller, Simone, Silva, Clovis A., Flores, Francisco, Goilav, Beatrice, Avar Aydin, Pinar Ozge, Wenderfer, Scott E., Levy, Deborah M., Ravelli, Angelo, Khubchandani, Raju, Avcin, Tadej, Klein‐Gitelman, Marisa S., Ruperto, Nicolino, Feldman, Brian M., Ying, Jun, Battagliotti, Cristina, Brusco, Maria Isabel, Cuttica, Rubén, De Cunto, Carmen, Espada, Graciela, Farfan, Maximiliano, Garay, Stella, Marcantoni, Maria, Marcela, Alvarez, Meiorin, Silvia, Rama, Maria Elena, Russo, Ricardo, Torre Walsh, Carolina, Zamparo, Celso, Adib, Navid, Akikusa, Jonathan, Boros, Christina, Lee, Senq J., Mckay, Damien, Piper, Susan, Joos, Rik, Bica, Blanca, Campos, Leonardo, Cavalcanti, André, do Prado, Rogerio, Donner‐Maliki, Amanda, Fernandes, Taciana, Fonseca, Adriana, Gasparello de Almeida, Rozana, Guariento, Andressa, Gusman, Catherine, Jusan Fiorot, Fernanda, Knupp Oliveira, Sheila, Len, Claudio, Arruda Campos, Lucia M., Machado, Sandra, Marques, Luciana, Martins de Carvalho, Luciana, Moulin, Rodrigo, Pedroso, Soraya, Pileggi, Gecilmara, Romanelli, Paulo Roberto S., Saad‐Magalhaes, Claudia, Sakamoto, Ana, Santos, Maria Carolina, Silva, Marco Felipe, Spelling, Paulo, Sztajnbok, Slavio, Terreri, Maria, Cabral, David, Chédeville, Gaëlle, Ellsworth, Janet, Huber, Adam, Tucker, Lori, Houghton, Kristin, Borzutzky, Arturo, Ladino, Mabel, Norambuena, Ximena, Eraso, Ruth, Mosquera, Angela, Velasquez, Monica, Harjacek, Miroslav, Jelusic, Marija, Coto Hermosilla, Cecilia, Dolezalova, Pavla, Nielsen, Susan, Tineo, Carmen, Alegria, Mauricio, Dressler, Frank, Foell, Dirk, Ganser, Gerd, Hinze, Claas, Hufnagel, Markus, Lutz, Thomas, Trauzeddel, Ralf, Boiu, Sorina, Trachana, Maria, Tsitsami, Elena, Cifuentes, Mayra, Orbán, Ilonka, Aggarwal, Amita, Sawhney, Sujata, Butbul Aviel, Yonatan, Cimaz, Rolando, Maggio, Maria Cristina, Rumba‐Rozenfelde, Ingrid, Hashad, Soad, Lim, Sern Chin, Abud, Carlos, Burgos‐Vargas, Ruben, Carreño‐Manjarrez, Roberto, Enciso Pelaez, Sandra, Hernandez‐Huirache, Hayde, Maldonado Velázquez, Rocio, Orozco, Javier, Rodriguez‐Lozano, Ana Luisa, Rojas Pacheco, Omar Ernesto, Suárez Larios, Luz Maria, Vega, Gabriel, Ramírez Miramontes, Julia Verónica, Ruíz Lopez, Ivon Karina, Kamphuis, Sylvia, Schonenberg‐Meinema, Dieneke, Concannon, Anthony, Yan, Jaqueline, Jarquin Jaime, Martha, Al Abrawi, Safiya, Vega, Cynthia, Lopez‐Benitez, Jorge, Ibáñez Estrella, Amparo, Miraval, Tatiana, Dans, Leonia, Kimseng, Karen Joy, Opoka‐Winiarska, Violetta, Rutkowska‐Sak, Lidia, Smolewska, Elzbieta, Conde, Marta, Guedes, Margarida, del Valle, Enid, Quintero‐Del Rio, Ana, Ailioaie, Constantin, Sparchez, Mihaela, Alekseeva, Ekaterina, Keltsev, Vladimir, Al‐Mayouf, Sulaiman, Asiri, Abdurhman, Suwairi, Wafaa, Susic, Gordana, Vijatov‐Djuric, Gordana, Ang, Elizabeth, Arkachaisri, Thaschawee, Boteanu, Alina‐Lucica, Lopez‐Robledillo, Juan Carlos, Medrano San Ildefonso, Marta, Modesto, Consuelo, Calvo, Inmaculada, Sotoca‐Fernandez, Jorge, Bolt, Isabel, Vilaiyuk, Soamarat, Al‐Abadi, Eslam, Baildam, Eileen, Fotis, Lampros, Pain, Clare, Pilkington, Clarissa, Abulaban, Khalid, Barbar‐Smiley, Fatima, Binstadt, Bryce, Bohnsack, John, Boneparth, Alexis, Brown, Diane, Chira, Peter, Cron, Randy, Dedeoglu, Fatma, Eberhard, Anne, Gedalia, Abraham, Grom, Alexei, Henrickson, Michael, Hom, Christine, Huggins, Jennifer, Jerath, Rita, Jones, Jordan, Jung, Lawrence, Kingsbury, Daniel, Lai, Jamie, Lovell, Daniel, Nanda, Kabita, Nocton, James, Olson, Judyann, O’Neil, Kathleen, Onel, Karen, Punaro, Lynn, Reiff, Andreas, Rouster‐Stevens, Kelly, Ruth, Natasha, Schikler, Ken, Murphy Schmidt, Kara, Schulert, Grant, Shaham, Bracha, Singer, Nora, Smith, Judith, Sundel, Robert, Syverson, Grant, Vega‐Fernandez, Patricia, Vehe, Richard, Wagner‐Weiner, Linda, Cameto, Juan, Jurado, Rosario, and Maldonado, Irama

Abstract

To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood‐onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRIcSLE). Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLEmanagement were invited to define CRIcSLEand rate a total of 433 unique patient profiles for the presence/absence of CRIcSLE. Patient profiles included the following cSLEcore response variables (CRVs): global assessment of patient well‐being (patient‐global), physician assessment of cSLEactivity (MD‐global), disease activity index score (here, we used the Systemic Lupus Erythematosus Disease Activity Index), urine protein‐to‐creatinine ratio, and Child Health Questionnaire physical summary score. Percentage and absolute changes in these cSLE‐CRVs (baseline versus follow‐up) were considered in order to develop candidate algorithms and validate their performance (sensitivity, specificity, area under the receiver operating characteristic curve [AUC]; range 0–1). During an international consensus conference, unanimous agreement on a definition of CRIcSLEwas achieved; cSLEexperts (n = 13) concurred (100%) that the preferred CHILIalgorithm considers absolute changes in the cSLE‐CRVs. After transformation to a range of 0–100, a CHILIscore of ≥54 had outstanding accuracy for identifying CRIcSLE(AUC0.93, sensitivity 81.1%, and specificity 84.2%). CHILIscores also reflect minor, moderate, and major improvement for values exceeding 15, 68, and 92, respectively (all AUC≥0.92, sensitivity ≥93.1%, and specificity ≥73.4%). The CHILIis a new, seemingly highly accurate index for measuring CRIin cSLEover time. This index is useful to categorize the degree of response to therapy in children and adolescents with cSLE.

Published
2019
Full Text
View/download PDF

3. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

Author

Consolaro, Alessandro, Giancane, Gabriella, Alongi, Alessandra, van Dijkhuizen, Evert Hendrik Pieter, Aggarwal, Amita, Al-Mayouf, Sulaiman M, Bovis, Francesca, De Inocencio, Jaime, Demirkaya, Erkan, Flato, Berit, Foell, Dirk, Garay, Stella Maris, Lazăr, Călin, Lovell, Daniel J, Montobbio, Carolina, Miettunen, Paivi, Mihaylova, Dimitrina, Nielsen, Susan, Orban, Ilonka, Rumba-Rozenfelde, Ingrida, Magalhães, Claudia Saad, Shafaie, Nahid, Susic, Gordana, Trachana, Maria, Wulffraat, Nico, Pistorio, Angela, Martini, Alberto, Ruperto, Nicolino, Ravelli, Angelo, Abdwani, Reem, Aghighi, Yahya, Aiche, Maya-Feriel, Ailioaie, Constantin, Aktay Ayaz, Nuray, Al-Abrawi, Safiya, Alexeeva, Ekaterina, Anton, Jordi, Apostol, Adriana, Arguedas, Olga, Avcin, Tadej, Barone, Patrizia, Berntson, Lillemor, Boteanu, Alina Lucica, Boyko, Yaryna, Burgos-Vargas, Ruben, Calvo Penades, Inmaculada, Chédeville, Gaëlle, Cimaz, Rolando, Civino, Adele, Consolini, Rita, Constantin, Tamas, Cuttica, Ruben, Dallos, Tomas, Martin, Neil, Magni Manzoni, Silvia, De Cunto, Carmen, Dolezalova, Pavla, Ekelund, Maria, El Miedany, Yasser, Espada, Graciela, Estmann Christensen, Anne, Foeldvari, Ivan, Gallizzi, Romina, Ganser, Gerd, Gerloni, Valeria, Haas, Johannes-Peter, Harel, Liora, Harjacek, Miroslav, Hashad, Soad, Herlin, Troels, Herrera, Cristina, Hofer, Michael, Holzinger, Dirk, Horneff, Gerd, Huppertz, Hans-Iko, Iagăru, Nicolae, Ibanez Estrella, Amparo, Ioseliani, Maka, Joos, Rik, Knupp Oliveira, Sheila, Kamphuis, Sylvia, Kasapcopur, Ozgur, Katsicas, Maria Martha, Khubchandani, Raju, Kondi, Anuela, Kröger, Liisa, La Torre, Francesco, Laday, Matilda, Lahdenne, Pekka, Maggio, Maria Cristina, Magnolia, Maria Greca, Malagon, Clara, Malin, Merja, Martino, Silvana, Melo-Gomes, Jose Antonio, Mesa-del-Castillo, Pablo, Militaru, Andrea, Minden, Kirsten, Miniaci, Angela, Moradinejad, Mohammad Hasan, Morel Ayala, Zoilo, Nikishina, Irina, Norambuena, Ximena, Nordal, Ellen Berit, Pagava, Karaman, Panaviene, Violeta, Pastore, Serena, Pieropan, Sara, Podda, Rosa Anna, Pruunsild, Chris, Putto-Laurila, Anne, Quartier, Pierre, Remesal, Agustin, Rigante, Donato, Ringold, Sarah, Rutkowska-Sak, Lidia, Rygg, Marite, Saurenmann, Rotraud Katharina, Sawhney, Sujata, Scott, Christiaan, Shiari, Reza, Smolewska, Elzbieta, Sozeri, Betul, Swart, Joost Frans, Sztajnbok, Flavio, Torcoletti, Marta, Tsitsami, Elena, Tzaribachev, Nikolay, Unsal, Erbil, Uziel, Yosef, Vähäsalo, Paula, Varbanova, Boriana, Vargova, Veronika, Vesely, Richard, Vijatov-Djuric, Gordana, Vilaiyuk, Soamarat, Vojinovic, Jelena, Vougiouka, Olga, Weiss, Pamela, and Wouters, Carine

Abstract

To our knowledge, the characteristics and burden of childhood arthritis have never been studied on a worldwide basis. We aimed to investigate, with a cross-sectional study, the prevalence of disease categories, treatment methods, and disease status in patients from across different geographical areas and from countries with diverse wealth status.

Published
2019
Full Text
View/download PDF

4. Corrigendum to The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort.

Author

Bustaffa, Marta, Koné-Paut, Isabelle, Ozen, Seza, Amaryan, Gayane, Papadopoulou-Alataki, Efimia, Gallizzi, Romina, Carrabba, Maria, Aviel, Yonatan Butbul, Cantarini, Luca, Alessio, Maria, Anton, Jordi, Obici, Laura, Gok, Faysal, Batu, Ezgi Deniz, Moreno, Estefania, Brogan, Paul, Trachana, Maria, Simonini, Gabriele, Rigante, Donato, and Uziel, Yosef

Published
2023
Full Text
View/download PDF

5. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

Author

Ruperto, Nicolino, Pistorio, Angela, Oliveira, Sheila, Zulian, Francesco, Cuttica, Ruben, Ravelli, Angelo, Fischbach, Michel, Magnusson, Bo, Sterba, Gary, Avcin, Tadej, Brochard, Karine, Corona, Fabrizia, Dressler, Frank, Gerloni, Valeria, Apaz, Maria T, Bracaglia, Claudia, Cespedes-Cruz, Adriana, Cimaz, Rolando, Couillault, Gerard, Joos, Rik, Quartier, Pierre, Russo, Ricardo, Tardieu, Marc, Wulffraat, Nico, Bica, Blanca, Dolezalova, Pavla, Ferriani, Virginia, Flato, Berit, Bernard-Medina, Ana G, Herlin, Troels, Trachana, Maria, Meini, Antonella, Allain-Launay, Emma, Pilkington, Clarissa, Vargova, Veronika, Wouters, Carine, Angioloni, Simona, and Martini, Alberto

Abstract

Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial, the efficacy and safety of prednisone alone with that of prednisone plus either methotrexate or ciclosporin in children with new-onset juvenile dermatomyositis.

Published
2016
Full Text
View/download PDF

6. Ghrelin levels in patients with juvenile idiopathic arthritis: relation to anti–tumor necrosis factor treatment and disease activity.

Author

Karagiozoglou-Lampoudi, Thomais, Trachana, Maria, Agakidis, Charalampos, Pratsidou-Gertsi, Polyxeni, Taparkou, Anna, Lampoudi, Sotiria, and Kanakoudi-Tsakalidou, Florentia

Subjects
GHRELIN, TUMOR necrosis factors, RHEUMATOID arthritis treatment, NUTRITIONAL assessment, BODY mass index, BIOENERGETICS
Abstract

Abstract: Studies in adults with rheumatoid arthritis reported low serum ghrelin that increased following anti–tumor necrosis factor (TNF) infusion. Data on juvenile idiopathic arthritis (JIA) are lacking. The aim of this pilot study was to explore serum ghrelin levels in patients with JIA and the possible association with anti-TNF treatment, disease activity, and nutritional status. Fifty-two patients with JIA (14/52 on anti-TNF treatment) were studied. Juvenile idiopathic arthritis was inactive in 3 of 14 anti-TNF–treated patients and in 11 of 38 non–anti-TNF-treated patients. The nutritional status, energy intake/requirements, appetite, and fasting serum ghrelin levels were assessed. Ghrelin control values were obtained from 50 individuals with minor illness matched for age, sex, and body mass index. Ghrelin levels in patients with JIA were significantly lower than in controls (P < .001, confidence interval [CI] = −101 to −331). Analysis according to anti-TNF treatment and disease activity showed that ghrelin levels were comparable to control values only in 3 patients with anti-TNF–induced remission. Ghrelin in non–anti-TNF-treated patients in remission was low. Multiple regression analysis showed that disease activity (P = .002, CI = −84.16 to −20.01) and anti-TNF treatment (P = .003, CI = −82.51 to −18.33) were significant independent predictors of ghrelin after adjusting for other potential confounders. Ghrelin did not correlate with nutritional status, energy balance, and appetite. Serum ghrelin is low in patients with JIA and is restored to values similar to those in controls following anti-TNF–induced remission. Our study provides evidence that TNF blockade is independently associated with serum ghrelin, which possibly contributes to anti-TNF–induced remission. These preliminary results could form the basis for future research. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

7. The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort.

Author

Bustaffa, Marta, Koné-Paut, Isabelle, Ozen, Seza, Amaryan, Gayane, Papadopoulou-Alataki, Efimia, Gallizzi, Romina, Carrabba, Maria, Aviel, Yonatan Butbul, Cantarini, Luca, Alessio, Maria, Anton, Jordi, Obici, Laura, Gok, Faysal, Batu, Ezgi Deniz, Moreno, Estefania, Brogan, Paul, Trachana, Maria, Simonini, Gabriele, Rigante, Donato, and Uziel, Yosef

Abstract

New Eurofever/PRINTO classification criteria (EPCC) for Familial Mediterranean Fever (FMF) and other recurrent fevers have been recently developed, together with the classification of the pathogenicity of MEFV variants. To evaluate the impact in real life of both the EPCC and INSAID pathogenicity classification of MEFV variants in the large international Eurofever FMF cohort. Baseline demographic, genetic and clinical data of FMF patients included in the Eurofever registry were evaluated. The EPCC and the 2018 INSAID classification for MEFV variants were applied in all eligible FMF patients. Since November 2009, clinical information was available for 1012 FMF (532 males/480 females, 827 children/185 adults) from 119 centres. Complete data were available for 887 patients in whom 623 (70.2%) satisfied EPCC (EPCC+), while 264 (29.8%) did not (EPCC−). The majority of the EPCC− patients (172, 65.1%) displayed negative or non-informative genetics (monoallelic or biallelic benign variants, monoallelic variant of unknown significance). At baseline, colchicine was used in most of EPCC+ patients (88%) and in a lower percentage of EPCC− patients (69%, p < 0.0001), who were treated in a higher proportion with steroid or NSAID on demand (p = 0.003 and 0.008, respectively). Four percent of patients received Anti-IL-1 treatment. The combination of EPCC and the 2018 INSAID classification of MEFV variants is able to identify two distinct groups of patients, which differ in clinical characteristics, therapeutic approach and response to treatment. EPCC+ patients displayed the typical features of FMF, while EPCC− patients had a more variable phenotype with a lower percentage of response to colchicine. [Display omitted]. • The application of Eurofever/PRINTO classification criteria (EPCC) defines two distinct groups of patients, which differ in clinical characteristic, therapeutic approach and response to treatment. • Patients fulfilling the EPCC displayed higher rate of response to colchicine, in comparison to EPCC− patients. • The negativity of EPCC and the presence of non-informative genetic test should alert the physicians for the possibility of an alternative diagnosis and treatment in the context of an inflammatory phenotype. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results